Diasorin (DSRLF) Lowered to Hold at Zacks Investment Research
Diasorin (OTCMKTS:DSRLF) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “DiaSorin S.p.A. engages in the development, production and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which serves infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology clinical areas. DiaSorin S.p.A. is headquartered in Vercelli, Italy. “
Diasorin (DSRLF) remained flat at $$90.94 during midday trading on Tuesday. Diasorin has a fifty-two week low of $54.86 and a fifty-two week high of $93.25.
DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; gastrointestinal infections; autoimmunity; and cardiac and brain damages.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diasorin Spa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diasorin Spa and related companies with MarketBeat.com's FREE daily email newsletter.